|
gptkbp:instanceOf
|
biotechnology company
|
|
gptkbp:acquisition
|
TCR2 Therapeutics
T_cell_receptor_platform_from_the_University_of_Oxford
|
|
gptkbp:CEO
|
gptkb:Bahija_Jallal
|
|
gptkbp:clinicalTrials
|
Phase 1
public company
Phase 2
Phase 3
Phase 4
IMC-C103C for HPV-positive cancers
IMC-C103C for colorectal cancer
IMC-C103C for esophageal cancer
IMC-C103C for gastric cancer
IMC-C103C for head and neck cancer
IMC-C103C for ovarian cancer
IMC-C103C for pancreatic cancer
IMC-C103C in Phase 1
IMC-C103C in solid tumors
IMCgp100 for advanced melanoma
IMCgp100 for breast cancer
IMCgp100 for liver cancer
IMCgp100 for melanoma brain metastases
IMCgp100 for non-small cell lung cancer
IMCgp100 for renal cell carcinoma
IMCgp100 for squamous cell carcinoma.
IMCgp100 for uveal melanoma
IMCgp100 in Phase 2
IMCgp100 in melanoma
|
|
gptkbp:collaborations
|
gptkb:Eli_Lilly
gptkb:GSK
gptkb:University_of_Oxford
gptkb:UCL
|
|
gptkbp:employeeCount
|
200+
|
|
gptkbp:focus
|
T cell receptor technology
|
|
gptkbp:founded
|
2008
|
|
gptkbp:founder
|
gptkb:Bahija_Jallal
|
|
gptkbp:funding
|
Series B
Series C
IPO
|
|
gptkbp:headCoach
|
over 200 employees
|
|
gptkbp:headquarters
|
gptkb:Oxford,_United_Kingdom
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Immunocore
|
|
gptkbp:impact
|
T cell redirection
|
|
gptkbp:investmentFocus
|
gptkb:New_Enterprise_Associates
gptkb:Greylock_Partners
gptkb:Balyasny_Asset_Management
gptkb:Index_Ventures
gptkb:Sofinnova_Partners
gptkb:Union_Square_Ventures
gptkb:Foundry_Group
gptkb:Bessemer_Venture_Partners
gptkb:RRE_Ventures
gptkb:Redmile_Group
gptkb:Morningside_Ventures
gptkb:Insight_Partners
gptkb:Atlas_Venture
gptkb:SoftBank_Vision_Fund
gptkb:Venrock
gptkb:Sequoia_Capital
gptkb:Canaan_Partners
gptkb:Bullpen_Capital
gptkb:Benchmark_Capital
gptkb:Khosla_Ventures
gptkb:UpWest_Labs
gptkb:FMR_LLC
gptkb:Costanoa_Ventures
gptkb:General_Catalyst_Partners
gptkb:True_Ventures
gptkb:Sutter_Hill_Ventures
2021
Kleiner Perkins
$100 million
Y Combinator
Accel Partners
CQS
Adage Capital Management
OrbiMed
IVP
|
|
gptkbp:leads
|
IMC-C103C
IMCgp100
|
|
gptkbp:market
|
cancer treatment
viral infections
|
|
gptkbp:partnerships
|
gptkb:AstraZeneca
gptkb:Bristol-Myers_Squibb
gptkb:Pfizer
Merck KGaA
|
|
gptkbp:patentCitation
|
T cell receptor technology patents
|
|
gptkbp:platforms
|
T cell receptor platform
T cell redirecting platform
|
|
gptkbp:products
|
IMC-C103C
IMCgp100
|
|
gptkbp:research
|
$30 million from the UK government
$50 million from Wellcome Trust
|
|
gptkbp:research_areas
|
oncology
infectious diseases
|
|
gptkbp:research_focus
|
autoimmunity
immune-oncology
|
|
gptkbp:researchFocus
|
immune-oncology
|
|
gptkbp:researchInterest
|
gptkb:National_Cancer_Institute
gptkb:Cancer_Research_UK
|
|
gptkbp:stockExchange
|
gptkb:NASDAQ
|
|
gptkbp:stockSymbol
|
IMCR
|
|
gptkbp:supplyChain
|
IMC-C103C
IMCgp100
|
|
gptkbp:technology
|
TCRs
T cell engagers
|
|
gptkbp:tradedOn
|
gptkb:NASDAQ
|
|
gptkbp:type
|
public company
|
|
gptkbp:website
|
www.immunocore.com
|